Avadel Pharmaceuticals (AVDL) Cash & Equivalents (2016 - 2022)
Historic Cash & Equivalents for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $60.7 million.
- Avadel Pharmaceuticals' Cash & Equivalents rose 437.69% to $60.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $60.7 million, marking a year-over-year increase of 437.69%. This contributed to the annual value of $50.7 million for FY2021, which is 2929.92% down from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Cash & Equivalents stood at $60.7 million, which was up 437.69% from $54.1 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Cash & Equivalents high stood at $102.2 million for Q2 2020, and its period low was $9.3 million during Q4 2018.
- Moreover, its 5-year median value for Cash & Equivalents was $54.1 million (2022), whereas its average is $45.9 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' Cash & Equivalents crashed by 7646.11% in 2019 and then surged by 66330.22% in 2020.
- Avadel Pharmaceuticals' Cash & Equivalents (Quarter) stood at $9.3 million in 2018, then rose by 4.82% to $9.8 million in 2019, then skyrocketed by 633.8% to $71.7 million in 2020, then dropped by 29.3% to $50.7 million in 2021, then increased by 19.73% to $60.7 million in 2022.
- Its Cash & Equivalents stands at $60.7 million for Q3 2022, versus $54.1 million for Q2 2022 and $60.9 million for Q1 2022.